Swedish clinical-stage drug developer Cinclus Pharma (STO: CINPHA), a specialist in treatments for gastric acid-related diseases, had picked up Chinese approval for linaprazan glurate.
The outcome represents the firm’s first marketing approval in China. The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in the People’s Republic of China in 2025.